From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
“Being able to accurately calculate and forecast accruals is vital to our financial planning process and ability to meet our financial goals.”
Vice President | Finance
With stagnant net revenue growth, the pharmaceutical industry faces multiple factors compressing margins, including government regulations, private payer negotiations, evolving distribution channels, and broader economic pressures. As a result, manufacturers are witnessing a concerning decline in net revenue.
Pharmaceutical companies need to have control, visibility, and optimization to drive net revenue growth. IntegriChain’s Gross-to-Net (GTN) pharma solutions unlock hidden revenue potential and combat stagnant net revenue growth.
Here’s how IntegriChain tackles the biggest challenges facing Finance and Accounting teams:
Transparent and auditable forecasts for informed decision-making
Test different pricing strategies and market responses to perform what-if analysis
Accurate, Reliable Data with the ICyte platform
Transparent calculations and streamlined processes for enhanced auditability
Ensure accurate and compliant revenue recognition
ICyte Platform.
Being able to analyze the effect of variations and build models to assess how different contract structures and pricing strategies influence projected net revenue is a challenge for manufacturers. Fragmented data, siloed departments utilizing independent GTN spreadsheets, and the sheer complexity of pricing factors – fees, discounts, chargebacks, credits, rebates – all contribute to this challenge.
The ICyte Platform streamlines gross-to-net pharma modeling by facilitating seamless collaboration across your organization. Key stakeholders can now contribute critical inputs directly within the platform:
This unified approach empowers teams responsible for pricing, payer negotiations, and co-pay programs to model future scenarios within the same platform. The result? A dramatically simplified process for exchanging crucial forecast inputs, leading to:
GTN Consulting.
Take the guesswork out of pharmaceutical financial management. IntegriChain empowers you to overcome the data, process, and resource limitations hindering accurate pharma gross-to-net (GTN) and net-pricing visibility.
We understand the intricate dependencies between GTN, channel, patient, and payer data.
IntegriChain offers a complete suite for pharmaceutical gross-to-net management solutions:
Empower your team to make data-driven decisions and unlock sustainable growth.
ICyte: Explore the Industry’s Only Integrated Net Revenue Platform.
The pharma gross-to-net process, essential for understanding net revenue, demands a keen awareness of every piece of data and business drivers upstream.s.
Read the Post
Learn how pharmaceutical manufacturers saved on time and cost with ICyte Gross-To-Net adoption.
Download now
